Aadi Bioscience, Inc. (AADI)

NASDAQ: AADI · IEX Real-Time Price · USD
5.01
0.00 (0.00%)
At close: Sep 25, 2023, 12:00 AM
5.00
-0.01 (-0.20%)
Pre-market: Sep 26, 2023, 8:00 AM EDT
Market Cap 122.84M
Revenue (ttm) 21.54M
Net Income (ttm) -61.58M
Shares Out 24.52M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 218
Open 5.01
Previous Close 5.01
Day's Range 4.90 - 5.05
52-Week Range 4.90 - 14.77
Beta 0.13
Analysts Strong Buy
Price Target 45.00 (+798.2%)
Earnings Date Nov 8, 2023

About AADI

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is he... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 89
Stock Exchange NASDAQ
Ticker Symbol AADI
Full Company Profile

Financial Performance

In 2022, AADI's revenue was $15.22 million, an increase of 1258.57% compared to the previous year's $1.12 million. Losses were -$60.51 million, -45.35% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for AADI stock is "Strong Buy" and the 12-month stock price forecast is $45.0.

Price Target
$45.0
(798.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

LOS ANGELES , Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR path...

5 days ago - PRNewsWire

Aadi Bioscience to Participate at Upcoming Investor Conferences

LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined canc...

21 days ago - PRNewsWire

Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to includ...

6 weeks ago - PRNewsWire

Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update

Company to Host Conference Call and Webcast on Wednesday, August 9, 2023 LOS ANGELES , Aug. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company f...

7 weeks ago - PRNewsWire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FGENINGNSILKTHRX
2 months ago - Benzinga

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES , May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetica...

4 months ago - PRNewsWire

Aadi Bioscience to Participate in Upcoming Investor Events

LOS ANGELES, May 23, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetical...

4 months ago - PRNewsWire

Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial

Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 4...

4 months ago - PRNewsWire

Aadi Bioscience to Report First Quarter 2023 Results and Operational Update

Company to Host Conference Call and Webcast on Wednesday, May 10, 2023 LOS ANGELES , May 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focu...

5 months ago - PRNewsWire

Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES , April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...

5 months ago - PRNewsWire

Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...

5 months ago - PRNewsWire

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023

LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetic...

6 months ago - PRNewsWire

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update

Total revenue on FYARRO® sales of $15.2 million for FY 2022 PRECISION 1 trial preliminary data expected in the second quarter of 2023 Conference call to be held today at 8:30 am EDT LOS ANGELES , Marc...

6 months ago - PRNewsWire

Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors

LOS ANGELES , March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...

6 months ago - PRNewsWire

Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer

LOS ANGELES , March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...

6 months ago - PRNewsWire

Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update

Company to Host Conference Call and Webcast on March 28, 2023 LOS ANGELES , March 15, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on...

6 months ago - PRNewsWire

Aadi Bioscience Announces Leadership Transition

LOS ANGELES , March 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alter...

7 months ago - PRNewsWire

Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference

LOS ANGELES , Feb. 22, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetic...

7 months ago - PRNewsWire

Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

Trial-in-progress poster showcases clinical trial design for PRECISION 1 and two additional posters demonstrate favorable durability of response and long-term safety of nab-sirolimus in the completed ...

11 months ago - PRNewsWire

Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update

Completed $72.5 million PIPE financing extending cash runway into 2025 PRECISION 1 trial on-track with preliminary data expected in the first half of 2023 24% revenue growth of FYARRO® (nab-sirolimus)...

11 months ago - PRNewsWire

Aadi Bioscience Announces Planned Leadership Transition

LOS ANGELES , Nov. 8, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with altera...

11 months ago - PRNewsWire

Aadi Bioscience to Present at Upcoming Investor Conferences

LOS ANGELES , Nov. 3, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetica...

11 months ago - PRNewsWire

Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update

Company to Host Conference Call and Webcast on November 9 LOS ANGELES , Nov. 2, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on devel...

11 months ago - PRNewsWire

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium

Nab-sirolimus added to KRAS inhibitor treatment demonstrated significantly greater antitumor activity and tumor regressions compared to the KRAS inhibitors alone The KRAS inhibitor combinations with n...

11 months ago - PRNewsWire

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation

SAN DIEGO and LOS ANGELES , Oct. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial s...

Other symbols: MRTX
1 year ago - PRNewsWire